Article

Modern interpretation of giant cell tumor of bone: predominantly osteoclastogenic stromal tumor.

Department of Orthopaedic Surgery, Columbia University Medical Center, Columbia University, New York, NY 10032, USA.
Clinics in orthopedic surgery 06/2012; 4(2):107-16. DOI:10.4055/cios.2012.4.2.107
Source: PubMed

ABSTRACT Owing to striking features of numerous multinucleated cells and bone destruction, giant cell tumor (GCT) of bone, often called as osteoclastoma, has drawn major attractions from orthopaedic surgeons, pathologists, and radiologists. The name GCT or osteoclastoma gives a false impression of a tumor comprising of proliferating osteoclasts or osteoclast precursors. The underlying mechanisms for excessive osteoclastogenesis are intriguing and GCT has served as an exciting disease model representing a paradigm of osteoclastogenesis for bone biologists. The modern interpretation of GCT is predominantly osteoclastogenic stromal cell tumors of mesenchymal origin. A diverse array of inflammatory cytokines and chemokines disrupts osteoblastic differentiation and promotes the formation of excessive multi-nucleated osteoclastic cells. Pro-osteoclastogenic cytokines such as receptor activator of nuclear factor kappa-B ligand (RANKL), interleukin (IL)-6, and tumor necrosis factor (TNF) as well as monocyte-recruiting chemokines such as stromal cell-derived factor-1 (SDF-1) and monocyte chemoattractant protein (MCP)-1 participate in unfavorable osteoclastogenesis and bone destruction. This model represents a self-sufficient osteoclastogenic paracrine loop in a localized area. Consistent with this paradigm, a recombinant RANK-Fc protein and bisphosphonates are currently being tried for GCT treatment in addition to surgical excision and conventional topical adjuvant therapies.

0 0
 · 
0 Bookmarks
 · 
89 Views
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: Giant cell tumour of bone is aggressive lesion, although benign. The involvement of the metacarpal bone is rare. Herein, we present a case of a 41-year-old male complaining of painless swelling of the posterior surface of the fourth right metacarpal bone. The radiological examination showed a large expansile lesion with cortical destruction involving the entire fourth metacarpal. Two stages treatment was performed: the first stage included total resection of the metacarpal bone together with partial excision of the surrounding muscles and reconstruction with fibular autograft and carpo-metacarpal arthrodesis; in the second stage a metacarpo-phalangeal cement-free endoprosthesis was done. We also discuss clinical, radiological, and therapeutical characteristics of this pathology.
    Journal of Radiotherapy and Medical Oncology. 01/2012; 18(2):73-77.
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: Objective: To study the clinical features, tumor characteristics and outcomes of giant cell tumors (GCTs) in the skull base based on long-term follow-up. We also report the largest series of GCTs in the temporal bone and the lateral skull base. Materials and Methods: A retrospective study was conducted of all GCTs managed at the Gruppo Otologico, a quaternary referral skull base institute, in Italy from 1993 to 2013. The clinical features, investigations, surgical management and follow-up were recorded. The surgical approaches used were infratemporal fossa approach (ITFA) type B and D and middle cranial fossa (MCF) approaches. Results and Observations: A total of 7 patients with GCTs of the skull base were treated at our institution. The principal complaints were hearing loss reported in 6 (85.71%) patients, tinnitus in 5 (71.43%) and swelling in 3 (42.9%). Pure-tone audiometry showed conductive hearing loss in 5 (71.43%) patients. High-resolution CT scan and MRI with gadolinium enhancement were done in all patients. Radiology showed involvement of the ITF and middle ear in 6 (85.71%) patients each, temporomandibular joint in 4 (57.14%) patients, invasions of the squamous part of the temporal bone, mastoid, MCF and greater wing of sphenoid in 3 (42.9%) patients each and the petrous bone in 2 (28.6%) patients. ITFA type B was applied as an approach for tumor removal in 5 (71.43%) patients, including a case where an additional MCF approach was employed, and ITFA type D and the transmastoid approach were applied in 1 (14.3%) patient each. Total tumor removal and successful cure was achieved in 6 (85.71%) patients. Subtotal removal leading to recurrence and eventual mortality was the result in 1 (14.3%) patient. Conclusions: A thorough knowledge of the anatomy of the skull base and the various skull base approaches is necessary to tackle GCTs. ITFA type B and D combined with MCF approaches provide good exposure of the tumor with minimal postoperative sequelae and good locoregional control. Recurrence due to either subtotal removal or suboptimal treatment may have disastrous consequences for the patient. © 2013 S. Karger AG, Basel.
    Audiology and Neurotology 11/2013; 19(1):12-21. · 2.32 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Giant cell tumor (GCT) of bone is a benign but locally aggressive neoplasm of bone. However, molecular mechanisms underlying osteolysis in GCT have not been deeply understood. The aim of this study was to investigate one of the possible mechanisms underlying the up-regulation of receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) expression. First, we performed an immunohistochemical study on transforming growth factor-β1 (TGF-β1) expression in 83 cases with GCT and found that increased TGF-β1 staining was significantly correlated with Campanacci stages(Spearman's correlation = 0.335, p = 0.002). Next, we investigated the mechanism of the effect of TGF-β1 on osteolysis of GCT and examined the effects of TGF-β1 plus or minus specific inhibitor of Smad3 (SIS3) on the expression of RANKL/OPG ratio at the mRNA and protein levels in two primary GCT cell lines. The results clearly indicated that TGF-β1 is capable of significantly increasing RANKL/OPG ratio (p GCT1 = 0.000, p GCT2 = 0.000) and that SIS3 is capable of reversing the ratio, suggesting that Smad3 is the key to TGF-β1-induced increased the ratio. In the co-culture system, we found that SIS3 reversed the effects of TGF-β1-induced osteoclast formation in the co-culture system (p GCT1 = 0.000, p GCT2 = 0.000). Our findings indicate that TGF-β1 plays an important role in the osteolysis of GCT via Smad3.
    Medical Oncology 09/2013; 30(3):606. · 2.14 Impact Factor

Full-text

View
1 Download
Available from